SCHEMBL2628636

SCHEMBL2628636

CC(C)[C@@H]1CC[C@@H](C)C[C@H]1C(=O)Nc1ccc(CCO)cc1

nearest known ligand 0.67

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 4/20 0.67
EPHX1 P07099 1/20 0.45
SERPINE1 P05121 1/20 0.40
NAMPT P43490 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
LMNA P02545 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP19A1 P11511 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10073862 0.91 TRPM8 (0.67) TRPM8EPHX1SERPINE1NAMPTNPC1
SCHEMBL661766 0.91 TRPM8 (0.67) TRPM8EPHX1SERPINE1NAMPTNPC1
SCHEMBL367373 0.90 TRPM8 (0.70) TRPM8EPHX1SERPINE1MEN1KMT2A
SCHEMBL2628643 0.90 TRPM8 (0.70) TRPM8EPHX1SERPINE1MEN1KMT2A
SCHEMBL15133477 0.90 TRPM8 (0.70) TRPM8EPHX1SERPINE1MEN1KMT2A
SCHEMBL2628763 0.88 TRPM8 (0.70) TRPM8EPHX1SERPINE1MEN1KMT2A
SCHEMBL14022692 0.87 TRPM8 (0.69) TRPM8EPHX1SERPINE1MEN1KMT2A
SCHEMBL18812290 0.86 TRPM8 (0.62) TRPM8EPHX1SERPINE1NAMPTMEN1
SCHEMBL2289957 0.86 TRPM8 (0.62) TRPM8EPHX1SERPINE1NAMPTNPC1
SCHEMBL12420570 0.86 TRPM8 (0.62) TRPM8EPHX1SERPINE1NAMPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389730-B2 Compositions and methods for the treatment of disease associated with TRP-P8 expression DENDREON CORPORATION (US) 2013-03-05 US disclosed
US-8389730-B2 Compositions and methods for the treatment of disease associated with TRP-P8 expression DENDREON CORPORATION (US) 2013-03-05 US disclosed
US-20120094977-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION DENDREON CORPORATION (US) 2012-04-19 US disclosed
US-20120094977-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION DENDREON CORPORATION (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094977-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION TRPC4, TRPC3, TRPC1 TRPM8 8/4885EPHX1 2270/4885SERPINE1 2822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.